wclc 2026
gallery
Relive the energy of WCLC 2026 in Seoul through photos from across the Conference.
Access Password: WCLC2026
Watch
on-demand
Don’t wait to hear the research discussed in Seoul. Catch up on WCLC 2026 sessions and presentations, with on-demand access to key scientific content from the Conference.
CME Certificate/ Certificate of Attendance
Claim your CME Certificate/Certificate of Attendance from September 15 through December 31, 2026 on the IASLC Lung Cancer 360 platform.
How to Access Recordings and Slides
WCLC 2026 BY THE NUMBERS
E-Posters
The moments that
brought us together.
From the science on stage to the connections in between. Relive the energy of WCLC 2026 in Seoul.
Select a photo to explore
WCLC NEWS
-
Zidesamtinib Demonstrates a High Objective Response Rate in TKI-Naïve Patients with Advanced ROS1-Positive NSCLC
Researcher Alexander Drilon, MD, said at a median follow-up duration of 15.2 months, the objective response rate was 94%, and the complete response rate was 15%.
-
T-DXd Poised for Shift to Frontline in HER2-Mutated Metastatic NSCLC
Julia Rotow, MD, said first-line trastuzumab deruxtecan monotherapy significantly improved progression-free survival compared with chemo-immunotherapy in the global phase III DESTINY-Lung04 trial.
-
First-line Zipalertinib Plus Chemotherapy Improves PFS in NSCLC with EGFR Exon 20 Insertions
Investigator Daniel Shao-Weng Tan, BSc, MBBS, MRCP, PhD, said in the REZILIENT 3 study, the curve separated early and appeared to widen over time, with clear durable separation up to the 15-month mark.
-
Sacituzumab Govitecan-Pembrolizumab Combination Will Not Supplant Pembrolizumab Monotherapy in PD-L1-High NSCLC
Although it showed a numerically longer PFS than pembrolizumab monotherapy, Giannis Mountzios, MD, MSc, PhD, said adding sacituzumab govitecan did not result in statistically significant improvements in PFS or OS in the phase III EVOKE-03 trial.
-
Multidisciplinary Teamwork Honored at WCLC 2026
The IASLC’s Cancer Care Team Award recognizes specialists from multiple disciplines who collaborate to improve patient care.
-
Overall Survival Benefit Seen in Interim Analysis of ARTEMIS-008 Signals Rapidly Expanding Landscape of ADC-Based Therapies in Small Cell Lung Cancer
Prof. Jie Wang, MD, said risvutatug rezetecan, a B7-H3-directed antibody-drug conjugate, demonstrated an overall survival benefit compared with topotecan in patients with relapsed SCLC.
"
WCLC is always an impressive conference and I always find exciting information that I can use to develop new treatment regiments for my patients.
Yanyan Wang
IASLC Member – China
"
WCLC is always a highlight of my year! As a pathologist, it’s fabulous to attend a multidisciplinary conference with people sharing ideas and giving insights from every perspective.
Keith Kerr
IASLC Member – United Kingdom
"
The WCLC atmosphere is amazing! As a medical student, the opportunity to hear from and talk to the biggest doctors in the industry is an experience of a lifetime.
Sanad Alhushki
Medical Student – Jordan